Agenus Inc. , a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

What they say: "Our Rosemary Mint Scalp and Hair Oil is a nutrient-rich, intensive formula meant to help you address your ...

Leading trichologists explain the importance of having a healthy scalp and why the best scalp serums can be used to promote ...

At JP Morgan last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Paul Hastings, the CEO of Nkarta, to talk ...

The hotel David Marsh reserved in Cancun, Mexico, is not responding to his questions — but it's keeping his money. Can ...

SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market ...

The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...

NKGen Biotech (NKGN) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, for the investigation ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health ...